• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Axsome Therapeutics, Inc. (AXSM) Stock Price, News & Analysis

Axsome Therapeutics, Inc. (AXSM) Stock Price, News & Analysis

Currency in USD Disclaimer

$100.13

$1.78

(1.81%)

Day's range
$98.16
Day's range
$100.24
50-day range
$80.85
Day's range
$105
  • Country: US
  • ISIN: US05464T1043
52 wk range
$64.11
Day's range
$105
  • CEO: Dr. Herriot Tabuteau M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.00
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (AXSM)
  • Company Axsome Therapeutics, Inc.
  • Price $100.13
  • Changes Percentage (1.81%)
  • Change $1.78
  • Day Low $98.16
  • Day High $100.24
  • Year High $105.00

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/18/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $133.00
  • High Stock Price Target $180.00
  • Low Stock Price Target $106.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$6.45
  • Trailing P/E Ratio -11.46
  • Forward P/E Ratio -11.46
  • P/E Growth -11.46
  • Net Income $-239,238,000

Income Statement

Quarterly

Annual

Latest News of AXSM

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Axsome Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of AXSM in the last quarter?

    In the last quarter Axsome Therapeutics, Inc. earnings were on Tuesday, November, 12th. The Axsome Therapeutics, Inc. maker reported -$1.34 EPS for the quarter, beating analysts' consensus estimates of -$1.38 by $0.04.

  • What is the Axsome Therapeutics, Inc. stock price today?

    Today's price of Axsome Therapeutics, Inc. is $100.13 — it has increased by +1.81% in the past 24 hours. Watch Axsome Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Axsome Therapeutics, Inc. release reports?

    Yes, you can track Axsome Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Axsome Therapeutics, Inc. stock forecast?

    Watch the Axsome Therapeutics, Inc. chart and read a more detailed Axsome Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Axsome Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Axsome Therapeutics, Inc. stock ticker.

  • How to buy Axsome Therapeutics, Inc. stocks?

    Like other stocks, AXSM shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Axsome Therapeutics, Inc.'s EBITDA?

    Axsome Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Axsome Therapeutics, Inc.’s financial statements.

  • What is the Axsome Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.8841019956, which equates to approximately -88.41%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Axsome Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Axsome Therapeutics, Inc.'s financials relevant news, and technical analysis. Axsome Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Axsome Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Axsome Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Axsome Therapeutics, Inc. for its last quarter?

    Axsome Therapeutics, Inc. published it's last quarterly revenues at $104.76 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.